Abstract:
Objective: Significant morbidity and mortality from SARS-CoV-2 has been experienced in America, Europe and Asia; whereas, the number of infections and deaths in sub-Sahara Africa (SSA) has remained comparatively low. One hypothesis is that population in SSA has been exposed to other coronaviruses prior to the COVID-19 pandemic and resulted in some degree of cross-protection against SARS-CoV-2 infection and pathogenesis. Our goal was to evaluate this hypothesis by comparing SARS-CoV-2 cross-reactive antibodies in pre-pandemic plasma samples collected from SSA and USA.
Method: Pre-COVID-19 pandemic plasma samples from SSA and USA were collected and tested by immunofluorescence assay against the spike and nucleocapid proteins of all known human coronaviruses (HCoV).
Results: Significantly higher prevalence of SARS-CoV-2 serological cross-reactivity was detected in samples from SSA compared to USA. Majority of these cross-reactive samples crossrecognized SARS-CoV-2 nucleocapsid protein together with recognition of spike proteins from other HCoVs. Since nucleocapsid proteins from HCoV-NL63 and HCoV-229E were detected by majority of samples, it implicates prior exposure to these two HCoVs as the likely source for cross-reactive antibodies against SARS-CoV-2.
Conclusion: Low SARS-CoV-2 infection and disease in SSA appears to correlate with prepandemic serological cross-recognition of HCoVs, which are substantially more prevalent in SSA than USA
